Insulin resistance in diabetic nephropathy - Cause or consequence?

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 5, 2006, Pages 401-410

  Svensson, Maria ^a   Eriksson, Jan W ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

And cytokines; Chronic renal failure; Diabetic nephropathy; Glucose metabolism; Hormones; Insulin resistance

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FOLLITROPIN; GONADORELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR; INTERMEDIATE DENSITY LIPOPROTEIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PARATHYROID HORMONE; PIOGLITAZONE; PROLACTIN; RESISTIN; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; HEMODIALYSIS; HEREDITY; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY TRANSPLANTATION; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ALBUMINURIA; DIABETIC NEPHROPATHIES; HUMANS; INSULIN RESISTANCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 33749005935     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.648     Document Type: Review

References (146)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
3. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48: 1684-1699.
4. Yki-Jarvinen H, Koivisto VA. Insulin resistance in type I diabetes: prevalence, pathogenesis and therapeutic approaches. Ann Clin Res 1984; 16: 74-83.
5. Makimattila S, Virkamaki A, Malmstrom R, Utriainen T, Yki-Jarvinen H. Insulin resistance in type I diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab 1996; 81: 707-712.
6. Yki-Jarvinen H, Koivisto VA. Insulin sensitivity in newly diagnosed type 1 diabetics after ketoacidosis and after three months of insulin therapy. J Clin Enclocrinol Metab 1984; 59: 371-378.
7. DeFronzo RA, Alvestrand A. Glucose intolerance in uremia: site and mechanism. Am J Clin Nutr 1980; 33: 1438-1445.
8. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest 1981; 67: 563-568.
9. Eidemak I, Feldt-Rasmussen B, Kanstrup IL, Nielsen SL, Schmitz O, Strandgaard S. Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 1995; 38: 565-572.
10. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347.
11. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098.
12. Svensson M, Yu ZW, Eriksson JW. A small reduction in glomerular filtration is accompanied by insulin resistance in type I diabetes patients with diabetic nephropathy. Eur J Clin Invest 2002; 32: 100-109.
13. Stenvinkel P, Ottosson-Seeberger A, Alvestrand A. Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia. J Am Soc Nephrol 1995; 5: 1751-1760.
14. Vareesangthip K, Tong P, Wilkinson R, Thomas TH. Insulin resistance in adult polycystic kidney disease. Kidney Int 1997; 52: 503-508.
15. Foley RN, Culleton BF, Parfrey PS, et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997; 40: 1307-1312.
16. Muntner P, He J, Hamm L, Loria. C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-753.
17. Mann JF, Gerstein HC, Dulau-Florea I, Lonn E. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int Suppl 2003; 84: S192-S196.
18. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895-906.
19. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 2(Suppl. 32): 64-78.
20. Mogensen CE, Chachati A, Christensen CK, et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985; 9: 85-95.
21. Ruggenenti P, Perna A, Mosconi L, et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 1997; 63: S54-S57.
22. Balkau B, Charles MA, Drivsholm T, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-376.
23. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
24. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic significance of microalbutninuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992; 41: 836-839.
25. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; 2: 530-533.
26. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria [see comments]. Lancet 1993; 342: 883-887.
27. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800.
28. Nielsen S, Schmitz O, Orskov H, Mogensen CE. Similar insulin sensitivity in NIDDM patients with normo- and microalbuminuria. Diabetes Care 1995; 18: 834-842.
29. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia 1998; 41: 694-700.
30. Toft I, Bonaa KH, Eikrem J, Bendiksen AL, Iversen H, Jenssen T. Microalbuminuria in hypertension is not a determinant of insulin resistance. Kidney Int 2002; 61: 1445-1452.
31. Ekstrand AV, Groop PH, Gronhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant 1998; 13: 3079-3083.
32. Fujikawa R, Okubo M, Egusa G, Kohno N. Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow up study. Diabetes Res Clin Pract 2001; 53: 99-106.
33. Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes meltitus: a temporal perspective. Am J Physiol Renal Physiol 2004; 286: F442-F450.
34. Tucker BJ, Anderson CM, Thies RS, Collins RC, Blantz RC. Glomerular hemodynamic alterations during acute hyperinsulinemia in normal and diabetic rats. Kidney Int 1992; 42: 1160-1168.
35. Patari A, Karhapaa P, Taipale H, et al. A 100-kDa urinary protein is associated with insulin resistance in offspring of type 2 diabetic patients. Diabetologia 2005; 48: 1844-1850.
36. Svensson M, Eriksson JW. No direct link between albumin excretion rate and insulin resistance - a study in type 1 diabetes patients with mild nephropathy. Horm Metab Res 2002; 34: 254-259.
37. Freed MI, Weston WM, Viberti G. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. Diabetologia 1999; 42: A230.
38. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12.
39. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complicat 2000; 14: 250-254.
40. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50: 1193-1196.
41. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and National Kidney Foundation stratification. Am J Kidney Dis 2002; 39: SI-266.
42. Schmitz O, Alberti KG, Christensen NJ, et al. Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. Metabolism 1985; 34: 465-473.
43. Pedersen O, Schmitz O, Hjollund E, Richelsen B, Hansen HE. Postbinding defects of insulin action in human adipocytes from uremic patients. Kidney Int 1985; 27: 780-784.
44. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Intl Suppl 1997; 62: S48-S52.
45. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type 11 diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992; 90: 1323-1327.
46. Castellino P, DeFronzo RA. Glucose metabolism and the kidney. Semin Nephrol 1990; 10: 458-463.
47. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 1998; 13: 2833-2841.
48. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab 2000; 26: 254-264.
49. Groop PH, Elliott T, Ekstrand A, et al. Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 1996; 45: 974-979.
50. Wanner C, Quaschning T. Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens 2001; 10: 195-201.
51. Jensen T, Stender S, Deckert T. Abnormalities in plasmas concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1988; 31: 142-145.
52. Attman PO, Nyberg G, William-Olsson T, Knight-Gibson C, Alaupovic P. Dyslipoproteinemia in diabetic renal failure. Kidney Int 1992; 42: 1381-1389.
53. Rigalleau V, Blanchetier V, Combe C, et al. A low-protein diet improves insulin sensitivity of endogenous glucose production in predialytic uremic patients. Am J Clin Nutr 1997; 65: 1512-1516.
54. Boden G. Fatty acids and insulin resistance. Diabetes Care 1996; 19: 394-395.
55. Schmitz O. Peripheral and hepatic resistance to insulin and hepatic resistance to glucagon in uraemic subjects. Studies at physiologic and supraphysiologic hormone levels. Acta Endocrinol (Copenh) 1988; 118: 125-134.
56. Penno G, Miccoli R, Pucci L, et al. Insulin resistance and microvascular complications in Type 1 diabetes: the Italian cohort of the Eurodiab Prospective Complications Study. Diabetologia 2004; 47: A22.
57. Vedovato M, Dodesini AR, Lepore G, Tiengo A, Trevisan R. Insulin resistance as a progression promotor in diabetic nephropathy. Diabetologia 2004; 47: A21.
58. Penno G, Miccoli R, Pucci L, et al. Metabolic syndrome and nephropathy in type 1 diabetes: the Italian cohort of the Eurodiab IDDM Complications Study. Diabetologia 2005; 48: A373.
59. De Cosmo S, Trevisan R, Minenna A, et al. Impact of insulin resistance/ metabolic syndrome on glomerular filtration rate in patients with type 2 diabetes. Diabetologia 2005; 48: A372.
60. Thorn LM, Forsblom C, Fagerudd J, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane Study). Diabetes Care 2005; 28: 2019-2024.
61. Mak RH. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int 1998; 54: 603-607.
62. Mak RH. Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol 1996; 270: F839-F844.
63. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia [see comments]. Nephron 1992; 61: 377-382.
64. Cumin F, Baum HP, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord 1996; 20: 1120-1126.
65. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 1983; 244: E517-E527.
66. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev 1998; 19: 608-624.
67. Tonshoff B, Blum WF, Mehls O. Insulin-like growth factors (IGF) and IGF binding proteins in children with chronic renal failure. Prog Growth Factor Res 1995; 6: 481-491.
68. Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 1985; 34: 1152-1159.
69. Schmitz O. Absence of diurnal plasma prolactin rhythm in diabetic and non-diabetic uraemic patients. Acta Endocrinol (Copenh) 1984; 105: 173-178.
70. Feneberg R, Schaefer F, Veldhuis JD. Neuroendocrine adaptations in renal disease. Pediatr Nephrol 2003; 18: 492-497.
71. Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW. Free and total insulin-like growth factor I (IGF-1), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2809-2815.
72. Johannsson G, Ahlmen J. End-stage renal disease: endocrine aspects of treatment. Growth Horm IGF Res 2003; 13(Suppl. A): S94-S101.
73. Bereket A, Lang CH, Wilson TA. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 1999; 31: 172-181.
74. Hedman CA, Frystyk J, Lindstrom T, et al. Residual beta-cell function more than glycemic control determines abnormalities of the insulin-like growth factor system in type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 6305-6309.
75. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-29.
76. Cherrington AD. Banting lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999; 48: 1198-1214.
77. DeFronzo RA, Andres R, Edgar P, Walker WG. Carbohydrate metabolism in uremia: a review. Medicine (Baltimore) 1973; 52: 469-481.
78. Chiu KC, Chuang LM, Lee NP, et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 2000; 49: 1501-1505.
79. Kumar S, Olukoga AO, Gordon C, et al. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994; 40: 47-53.
80. Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12: 933-938.
81. Dullaart RP, Ubels FL, Hoogenberg K, et al. Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition. J Clin Endocrinol Metab 1995; 80: 3002-3008.
82. Heaton A, Johnston DG, Haigh JW, Ward MK, Alberti KG, Kerr DN. Twenty-four hour hormonal and metabolic profiles in uraemic patients before and during treatment with continuous ambulatory peritoneal dialysis. Clin Sci (Lond) 1985; 69: 449-457.
83. Vierhapper H, Derfler K, Nowotny P, Hollenstein U, Waldhausl W. Impaired conversion of cortisol to cortisone in chronic renal insufficiency - a cause of hypertension or an epiphenomenon? Acta Endocrinol (Copenh) 1991; 125: 160-164.
84. Homma M, Tanaka A, Hino K, et al. Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure. Metabolism 2001; 50: 801-804.
85. Vogt B, Dick B, N'Gankam V, Frey FJ, Frey BM. Reduced 11 beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome. J Clin Endocrinol Metab 1999; 84: 811-814.
86. Prem AR, Punekar SV, Kalpana M, Kelkar AR, Acharya VN. Male reproductive function in uraemia: efficacy of haemodialysis and renal transplantation. Br J Urol 1996; 78: 635-638.
87. Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16: 991-997.
88. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996; 20: 291-302.
89. Jansson PA, Eliasson B, Lindmark S, Eriksson JW. Endocrine abnormalities in healthy first-degree relatives of type 2 diabetes patients-potential role of steroid hormones and leptin in the development of insulin resistance. Eur J Clin Invest 2002; 32: 172-178.
90. Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985; 28: 138-142.
91. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 2003; 26: 341-346.
92. Yavuz D, Deyneli O, Akpinar I, et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 2003; 149: 187-193.
93. Girard J. Is leptin the link between obesity and insulin resistance? Diabetes Metab 1997; 23(Suppl. 3): 16-24.
94. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54: 1267-1275.
95. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-1079.
96. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807-825.
97. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
98. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
99. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255: 439-447.
100. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42: 62-66.
101. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300.
102. Stenvinkel P, Marchlewska A, Pecoits-Filho R, et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004; 65: 274-281.
103. Frystyk J, Tarnow L, Krarup Hansen T, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005; 48: 1911-1918.
104. Saraheimo M, Forsblom C, Fagerudd J, et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005; 28: 1410-1414.
105. Hadjadj S, Aubert R, Fumeron F, et al. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia 2005; 48: 1088-1092.
106. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
107. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
108. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-343.
109. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
110. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
111. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896.
112. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Intl Suppl 2002; 80: S103-108.
113. Spaia S, Pangalos M, Askepidis N, et al. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 2000; 84: 320-325.
114. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-499.
115. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-1010.
116. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
117. Nielsen S, Hove KY, Dollerup J, et al. Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes. Diabetes Obes Metab 2001; 3: 463-471.
118. Fliser D, Keller C, Bahrmann P, et al. Altered action of angiotensin II in patients with type 2 diabetes mellitus of recent onset. J hypertens 1997; 15: 293-299.
119. Yildiz A, Sever MS, Demirel S, et al. Improvement of uremic autonomic dysfunction after renal transplantation: a heart rate variability study. Nephron 1998; 80: 57-60.
120. Vita G, Savica V, Milone S, Trusso A, Bellinghieri G, Messina C. Uremic autonomic neuropathy: recovery following bicarbonate hemodialysis. Clin Nephrol 1996; 45: 56-60.
121. Foss CH, Vestbo E, Froland A, Gjessing HJ, Mogensen CE, Damsgaard EM. Autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects is associated with urinary albumin excretion rate and 24-h ambulatory blood pressure: the Fredericia Study. Diabetes 2001; 50: 630-636.
122. Lindmark S, Wildund U, Bjerle P, Eriksson JW. Does the autonomic nervous system play a role in the development of insulin resistance? A study on heart rate variability in first-degree relatives of Type 2 diabetes patients and control subjects. Diabet Med 2003; 20: 399-405.
123. Lindmark S, Lonn L, Wiklund U, Tufvesson M, Olsson T, Eriksson JW. Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes Res 2005; 13: 717-728.
124. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 2001; 23: 45-55.
125. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072.
126. Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 2003; 27: 88-94.
127. Svensson M, Eriksson JW. A decline in glomerular filtration rate over time does not reduce insulin sensitivity in patients with type 1 diabetes. Diabetologia 2004; 47: A388.
128. Kumar S, Davies M, Zakaria Y, et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994; 70: 440-443.
129. Huang Y, Ishizuka T, Miura A, et al. Effect of 1 alpha,25-dihydroxy vitamin D3 and vitamin E on insulin-induced glucose uptake in rat adipocytes. Diabetes Res Clin Pract 2002; 55: 175-183.
130. Rudnicki PM, Molsted-Pedersen L. Effect of 1,25-dihydroxy-cholecalciferol on glucose metabolism in gestational diabetes mellitus. Diabetologia 1997; 40: 40-44.
131. Ferraris JR, Domene HM, Escobar ME, Caletti MG, Ramirez JA, Rivarola MA. Hormonal profile in pubertal females with chronic renal failure: before and under haemodialysis and after renal transplantation. Acta Endocrinol (Copenh) 1987; 115: 289-296.
132. Veldhuis JD, Wilkowski MJ, Zwart AD, et al. Evidence for attenuation of hypothalamic gonadotropin-releasing hormone (GnRH) impulse strength with preservation of GnRH pulse frequency in men with chronic renal failure. J Clin Endocrinol Metab 1993; 76: 648-654.
133. Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10: 1381-1388.
134. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
135. Stenvinkel P, Alvestrand A. inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337.
136. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002; 62: 963-970.
137. Fagerudd JA, Tarnow L, Jacobsen P, et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998; 47: 439-444.
138. Fagerudd JA, Pettersson-Fernholm KJ, Gronhagen-Riska C, Croop PH. The impact of a family history of Type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with Type I (insulin-dependent) diabetes mellitus. Diabetologia 1999; 42: 519-526.
139. Earle K, Walker J, Hill C, Viberti G. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992; 326: 673-677.
140. Yip J, Mattock M, Sethi M, Morocutti A, Viberti G. Insulin resistance in family members of insulin-dependent diabetic patients with microalbuminuria [letter]. Lancet 1993; 341: 369-370.
141. Fetita L-S, Sobngwi E, Leblanc H, et al. Non diabetic offspring of type 1 diabetic patients with nephropathy have a decreased insulin sensitivity. Diabetologia 2005; 48: A373.
142. Eliasson B, Smith U. Leptin levels in smokers and long-term users of nicotine gum. Eur J Clin Invest 1999; 29: 145-152.
143. Dzien A, Dzien-Bischinger C, Hoppichler F, Lechleitner M. The metabolic syndrome as a link between smoking and cardiovascular disease. Diabetes Obes Metab 2004; 6: 127-132.
144. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002; 25: 859-864.
145. Rudberg S, Stattin EL, Dahlquist G. Familial and perinatal risk factors for micro- and macroalbuminuria in young IDDM patients. Diabetes 1998, 47: 1121-1126.
146. Barzilay J, Warram JH, Bak M, Laffel LM, Canessa M, Krolewski AS. Predisposition to hypertension: risk factor for nephropathy and hypertension in IDDM. Kidney Int 1992; 41: 723-730.